Quantisnow Logo
Dashboard

SEC Form SC 13G/A filed by Akoya BioSciences Inc. (Amendment)

$AKYA
Biotechnology: Laboratory Analytical Instruments
Industrials
Get the next $AKYA alert in real time by email
SC 13G/A 1 zk2430729.htm SC 13G/A

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934

Akoya Biosciences, Inc.
(Name of Issuer)
 
Common Stock, Par Value $0.00001 per Share
(Title of Class of Securities)
 
 00974H104
(CUSIP Number)

December 31, 2023
(Date of Event which Requires Filing of this Statement)
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
☐ Rule 13d-1(b)
 
☒ Rule 13d-1(c)
 
☐ Rule 13d-1(d)
 
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
 

CUSIP No.
00974H104
1.
Names of Reporting Persons
 
aMoon Growth Fund II, L.P.
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
3.
SEC Use Only
 
4.
Citizenship or Place of Organization

Cayman Islands 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
Sole Voting Power
 
0
6.
 
Shared Voting Power
 
2,871,406
7.
 
Sole Dispositive Power
 
0
8.
 
Shared Dispositive Power
 
2,871,406
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
2,871,406
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
☐
11.
Percent of Class Represented by Amount in Row (9)
 
5.85%(1)
12.
Type of Reporting Person (See Instructions)
 
PN 

(1)
Based on 49,076,173 shares of Common Stock issued and outstanding at October 31, 2023, as reported in the Issuer’s Form 10-Q filed with the U.S. Securities and Exchange Committee on November 9, 2023.

Page 2 of 19 Pages

CUSIP No.
00974H104
1.
Names of Reporting Persons
 
aMoon Growth Fund II G.P., L.P.
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
3.
SEC Use Only
 
4.
Citizenship or Place of Organization

Cayman Islands
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
Sole Voting Power
 
0
6.
 
Shared Voting Power
 
2,871,406
7.
 
Sole Dispositive Power
 
0
8.
 
Shared Dispositive Power
 
2,871,406
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
2,871,406
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
☐
11.
Percent of Class Represented by Amount in Row (9)
 
5.85%(1)
12.
Type of Reporting Person (See Instructions)
 
PN 

(1)
Based on 49,076,173 shares of Common Stock issued and outstanding at October 31, 2023, as reported in the Issuer’s Form 10-Q filed with the U.S. Securities and Exchange Committee on November 9, 2023.
 
Page 3 of 19 Pages


CUSIP No.
00974H104
1.
Names of Reporting Persons
 
aMoon Growth II General Partner Ltd.
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
3.
SEC Use Only
 
4.
Citizenship or Place of Organization

Israel
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
Sole Voting Power
 
0
6.
 
Shared Voting Power
 
2,871,406
7.
 
Sole Dispositive Power
 
0
8.
 
Shared Dispositive Power
 
2,871,406
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
2,871,406
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
☐
11.
Percent of Class Represented by Amount in Row (9)
 
5.85%(1)
12.
Type of Reporting Person (See Instructions)
 
CO
 
(1)
Based on 49,076,173 shares of Common Stock issued and outstanding at October 31, 2023, as reported in the Issuer’s Form 10-Q filed with the U.S. Securities and Exchange Committee on November 9, 2023.

Page 4 of 19 Pages

CUSIP No.
00974H104
1.
Names of Reporting Persons
 
aMoon Edge Limited Partnership
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
3.
SEC Use Only
 
4.
Citizenship or Place of Organization

Cayman Islands
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
Sole Voting Power
 
0
6.
 
Shared Voting Power
 
205,789
7.
 
Sole Dispositive Power
 
0
8.
 
Shared Dispositive Power
 
205,789
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
205,789
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
☐
11.
Percent of Class Represented by Amount in Row (9)
 
0.42% (1) 
12.
Type of Reporting Person (See Instructions)
 
PN

(1)
Based on 49,076,173 shares of Common Stock issued and outstanding at October 31, 2023, as reported in the Issuer’s Form 10-Q filed with the U.S. Securities and Exchange Committee on November 9, 2023.

Page 5 of 19 Pages
 
CUSIP No.
00974H104
1.
Names of Reporting Persons
 
aMoon Edge GP Ltd.
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
3.
SEC Use Only
 
4.
Citizenship or Place of Organization

Cayman Islands
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
Sole Voting Power
 
0
6.
 
Shared Voting Power
 
205,789
7.
 
Sole Dispositive Power
 
0
8.
 
Shared Dispositive Power
 
205,789
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
205,789
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
☐
11.
Percent of Class Represented by Amount in Row (9)
 
0.42% (1) 
12.
Type of Reporting Person (See Instructions)
 
CO

(1)
Based on 49,076,173 shares of Common Stock issued and outstanding at October 31, 2023, as reported in the Issuer’s Form 10-Q filed with the U.S. Securities and Exchange Committee on November 9, 2023.

Page 6 of 19 Pages

CUSIP No.
00974H104
1.
Names of Reporting Persons
 
Hilliyon Holdings Ltd.
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
3.
SEC Use Only
 
4.
Citizenship or Place of Organization

Israel
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
Sole Voting Power
 
0
6.
 
Shared Voting Power
 
205,789
7.
 
Sole Dispositive Power
 
0
8.
 
Shared Dispositive Power
 
205,789
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
205,789
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
☐
11.
Percent of Class Represented by Amount in Row (9)
 
0.42% (1) 
12.
Type of Reporting Person (See Instructions)
 
CO

(1)
Based on 49,076,173 shares of Common Stock issued and outstanding at October 31, 2023, as reported in the Issuer’s Form 10-Q filed with the U.S. Securities and Exchange Committee on November 9, 2023.

Page 7 of 19 Pages

CUSIP No.
00974H104
1.
Names of Reporting Persons
 
Berko Capital Ltd.
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
3.
SEC Use Only
 
4.
Citizenship or Place of Organization

Israel
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
Sole Voting Power
 
0
6.
 
Shared Voting Power
 
205,789
7.
 
Sole Dispositive Power
 
0
8.
 
Shared Dispositive Power
 
205,789
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
205,789
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
☐
11.
Percent of Class Represented by Amount in Row (9)
 
0.42% (1) 
12.
Type of Reporting Person (See Instructions)
 
CO

(1)
Based on 49,076,173 shares of Common Stock issued and outstanding at October 31, 2023, as reported in the Issuer’s Form 10-Q filed with the U.S. Securities and Exchange Committee on November 9, 2023.

Page 8 of 19 Pages

CUSIP No.
00974H104
1.
Names of Reporting Persons
 
Dr. Yair C. Schindel
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
3.
SEC Use Only
 
4.
Citizenship or Place of Organization

Israel
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
Sole Voting Power
 
0
6.
 
Shared Voting Power
 
3,077,195
7.
 
Sole Dispositive Power
 
0
8.
 
Shared Dispositive Power
 
3,077,195
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
3,077,195
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
☐
11.
Percent of Class Represented by Amount in Row (9)
 
6.27% (1) 
12.
Type of Reporting Person (See Instructions)
 
IN

(1)
Based on 49,076,173 shares of Common Stock issued and outstanding at October 31, 2023, as reported in the Issuer’s Form 10-Q filed with the U.S. Securities and Exchange Committee on November 9, 2023.

Page 9 of 19 Pages
 
CUSIP No.
00974H104
1.
Names of Reporting Persons
 
Dr. Tomer Berkovitz
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
3.
SEC Use Only
 
4.
Citizenship or Place of Organization

Israel
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
Sole Voting Power
 
0
6.
 
Shared Voting Power
 
205,789
7.
 
Sole Dispositive Power
 
0
8.
 
Shared Dispositive Power
 
205,789
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
 
205,789
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
☐
11.
Percent of Class Represented by Amount in Row (9)
 
0.42% (1) 
12.
Type of Reporting Person (See Instructions)
 
IN

(1)
Based on 49,076,173 shares of Common Stock issued and outstanding at October 31, 2023, as reported in the Issuer’s Form 10-Q filed with the U.S. Securities and Exchange Committee on November 9, 2023.

Page 10 of 19 Pages

Item 1(a)            Name of Issuer
 
Akoya Biosciences, Inc. (the “Issuer”).
 
Item 1(b)            Address of Issuer’s Principal Executive Offices
 

100 Campus Drive, 6th Floor, Marlborough, MA 01752.
 
Item 2(a)-(b)      Name of Person Filing; Address of Principal Business Office or, if none, Residence
 

 1.
aMoon Growth Fund II, L.P. (“aMoon”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
 

 2.
aMoon Growth Fund II G.P., L.P. (“aMoon G.P.”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
 

 3.
aMoon Growth II General Partner Ltd., (“aMoon Ltd.”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
 

 4.
aMoon Edge Limited Partnership (“aMoon Edge”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
 

 5.
aMoon Edge GP Ltd., (“aMoon Edge Ltd.”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
 

 6.
Hilliyon Holdings Ltd., (“Hilliyon”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
 

 7.
Berko Capital Ltd., an Israeli company (“Berko Capital”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
 

 8.
Dr. Yair C. Schindel (“Schindel”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
 

 9.
Dr. Tomer Berkovitz (“Berkovitz”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
 

The foregoing persons are hereinafter collectively referred to as the “Reporting Persons”.

Item 2(c)            Citizenship
 

aMoon is a Cayman Islands exempted limited partnership; aMoon G.P. is a Cayman Islands exempted limited partnership; aMoon Ltd. is an Israeli company; aMoon Edge is a Cayman Islands exempted limited partnership; aMoon Edge Ltd. is a Cayman Islands company; Hilliyon is an Israeli company; Berko Capital is an Israeli company; Schindel is an Israeli citizen and Berkovitz is an Israeli citizen.
 
Page 11 of 19 Pages
Item 2(d)            Title of Class of Securities
 

Common Stock, par value $0.00001 per share

Item 2(e)            CUSIP Number
 

00974H104
 
Item 3
If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
 

Not applicable.
 
Item 4                 Ownership

All share percentage calculation below are based on 49,076,173 shares of Common Stock issued and outstanding at October 31, 2023, as reported in the Issuer’s Form 10-Q filed with the U.S. Securities and Exchange Committee on November 9, 2023.

aMoon Growth Fund II, L.P.


 (a)
Amount beneficially owned:  2,871,406 shares of Common Stock.


(b)
Percent of Class: 5.85%


(c)
Number of shares as to which the person has:

(i)
Sole power to vote or direct the vote: 0

(ii)
Shared power to vote or to direct the vote: 2,871,406 shares of Common Stock

(iii)
Sole power to dispose or to direct the disposition of: 0

(iv)
Shared power to dispose or to direct the disposition of: 2,871,406 shares of Common Stock

aMoon Growth Fund II G.P., L.P.


 (a)
Amount beneficially owned:  2,871,406 shares of Common Stock.


(b)
Percent of Class: 5.85%


(c)
Number of shares as to which the person has:

(i)
Sole power to vote or direct the vote: 0

(ii)
Shared power to vote or to direct the vote: 2,871,406 shares of Common Stock

(iii)
Sole power to dispose or to direct the disposition of: 0

(iv)
Shared power to dispose or to direct the disposition of: 2,871,406 shares of Common Stock.

aMoon Growth II General Partner Ltd.


 (a)
Amount beneficially owned:  2,871,406 shares of Common Stock.


(b)
Percent of Class: 5.85%

Page 12 of 19 Pages
 

(c)
Number of shares as to which the person has:

(i)
Sole power to vote or direct the vote: 0

(ii)
Shared power to vote or to direct the vote: 2,871,406 shares of Common Stock

(iii)
Sole power to dispose or to direct the disposition of: 0

(iv)
Shared power to dispose or to direct the disposition of: 2,871,406 shares of Common Stock.

aMoon Edge Limited Partnership


 (a)
Amount beneficially owned:  205,789 shares of Common Stock.


(b)
Percent of Class: 0.42%


(c)
Number of shares as to which the person has:

(i)
Sole power to vote or direct the vote: 0

(ii)
Shared power to vote or to direct the vote: 205,789 shares of Common Stock

(iii)
Sole power to dispose or to direct the disposition of: 0

(iv)
Shared power to dispose or to direct the disposition of: 205,789 shares of Common Stock.

aMoon Edge GP Ltd.


 (a)
Amount beneficially owned:  205,789 shares of Common Stock.


(b)
Percent of Class: 0.42%


(c)
Number of shares as to which the person has:

(i)
Sole power to vote or direct the vote: 0

(ii)
Shared power to vote or to direct the vote: 205,789 shares of Common Stock

(iii)
Sole power to dispose or to direct the disposition of: 0

(iv)
Shared power to dispose or to direct the disposition of: 205,789 shares of Common Stock.

Hilliyon Holdings Ltd.


 (a)
Amount beneficially owned:  205,789 shares of Common Stock.


(b)
Percent of Class: 0.42%


(c)
Number of shares as to which the person has:

(i)
Sole power to vote or direct the vote: 0

(ii)
Shared power to vote or to direct the vote: 205,789 shares of Common Stock

(iii)
Sole power to dispose or to direct the disposition of: 0

(iv)
Shared power to dispose or to direct the disposition of: 205,789 shares of Common Stock.

Berko Capital Ltd.


 (a)
Amount beneficially owned:  205,789 shares of Common Stock.


(b)
Percent of Class: 0.42%


(c)
Number of shares as to which the person has:

(i)
Sole power to vote or direct the vote: 0

(ii)
Shared power to vote or to direct the vote: 205,789 shares of Common Stock

(iii)
Sole power to dispose or to direct the disposition of: 0

(iv)
Shared power to dispose or to direct the disposition of: 205,789 shares of Common Stock.

Page 13 of 19 Pages

Dr. Yair C. Schindel


 (a)
Amount beneficially owned: 3,077,195 shares of Common Stock.  (i) Schindel is the sole shareholder of aMoon Ltd. By virtue of such relationships, Schindel may be deemed to share voting and investment power with respect to the shares of Common Stock of the Issuer held by aMoon; (ii) aMoon Edge Ltd. is the sole general partner of aMoon Edge pursuant to the terms of the limited partnership agreement of aMoon Edge.  Hilliyon and Berko Capital are the sole shareholders of aMoon Edge Ltd. and Schindel is the sole shareholder of Hilliyon. By virtue of such relationships, Schindel may be deemed to share voting and investment power with respect to the shares of Common Stock of the Issuer held by aMoon Edge. Schindel disclaims beneficial ownership of the shares of Common Stock of the Issuer held by aMoon, aMoon G.P. aMoon Ltd., aMoon Edge, aMoon Edge Ltd., and Hilliyon, except to the extent of his pecuniary interest therein, if any.


(b)
Percent of Class: 6.27%


(c)
Number of shares as to which the  person has:

(i)
Sole power to vote or direct the vote: 0

(ii)
Shared power to vote or to direct the vote: 3,077,195  shares of Common Stock

(iii)
Sole power to dispose or to direct the disposition of: 0

(iv)
Shared power to dispose or to direct the disposition of: 3,077,195 shares of Common Stock.

Dr. Tomer Berkovitz


 (a)
Amount beneficially owned: 205,789 shares of Common Stock.  Hilliyon and Berko Capital are the sole shareholders of aMoon Edge Ltd., and Berkovitz is the sole shareholder of Berko Capital. By virtue of such relationships, Berkovitz may be deemed to share voting and investment power with respect to the shares of Common Stock of the Issuer held by aMoon Edge. Berkovitz disclaims beneficial ownership of the shares of Common Stock of the Issuer held by aMoon Edge, aMoon Edge Ltd. and Berko Capital, except to the extent of his pecuniary interest therein, if any.


(b)
Percent of Class: 0.42%


(c)
Number of shares as to which the  person has:

(i)
Sole power to vote or direct the vote: 0

(ii)
Shared power to vote or to direct the vote: 205,789  shares of Common Stock

(iii)
Sole power to dispose or to direct the disposition of: 0

(iv)
Shared power to dispose or to direct the disposition of: 205,789 shares of Common Stock

Item 5
Ownership of Five Percent or Less of a Class
 
Not applicable.
 
Item 6
Ownership of More than Five Percent on Behalf of Another Person
 
Not applicable.
 
Item 7
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
 
Not applicable.
 
Page 14 of 19 Pages
 
Item 8
Identification and Classification of Members of the Group
 

Incorporated by reference to Items 2 and 4 of this Schedule 13G.
 
Item 9
Notice of Dissolution of Group
 

Not applicable.

Item 10
Certification
 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 15 of 19 Pages
Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
Dated: January 3, 2024
 
AMOON GROWTH FUND II L.P.
BY: AMOON GROWTH FUND II G.P., L.P., ITS GENERAL PARTNER
BY:  AMOON GROWTH II GENERAL PARTNER LTD., ITS GENERAL PARTNER
By:
/s/ Dr. Yair C. Schindel
 
Name:
Title:
Dr. Yair C. Schindel
Director
 
AMOON GROWTH FUND II G.P., L.P.,
BY:  AMOON GROWTH II GENERAL PARTNER LTD., ITS GENERAL PARTNER

By:
/s/ Dr. Yair C. Schindel
 
Name:
Title:
Dr. Yair C. Schindel
Director

AMOON GROWTH II GENERAL PARTNER LTD.
 
By:
/s/ Dr. Yair C. Schindel
 
Name:
Title:
Dr. Yair C. Schindel
Director
 
AMOON EDGE LIMITED PARTNERSHIP
BY:  AMOON EDGE GP LTD., ITS GENERAL PARTNER
 
By:
/s/ Dr. Yair C. Schindel
 
Name:
Title:
Dr. Yair C. Schindel
Director
 
Page 16 of 19 Pages

AMOON EDGE GP LTD.
 
By:
/s/ Dr. Yair C. Schindel
 
Name:
Title:
Dr. Yair C. Schindel
Director

HILLIYON HOLDINGS LTD.
 
By:
/s/ Dr. Yair C. Schindel
 
Name:
Title:
Dr. Yair C. Schindel
Director

BERKO CAPITAL LTD.
 
By:
/s/ Dr. Tomer Berkovitz
 
Name:
Title:
Dr. Tomer Berkovitz
Director

DR. YAIR C. SCHINDEL
/s/ Dr. Yair C. Schindel
  

DR. TOMER BERKOVITZ
 
/s/ Dr. Tomer Berkovitz
  

Page 17 of 19 Pages

EXHIBIT A TO SCHEDULE 13G

Joint Filing Agreement

The undersigned hereby agree that the Schedule 13G (the “Schedule 13G”), filed by the undersigned with respect to shares of Common Stock, par value $0.00001 per share, of Akoya Biosciences, Inc. is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Joint Filing Agreement (this “Agreement”) shall be included as an Exhibit to the Schedule 13G.  Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein.  This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.  

 IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement this 3ed day of January 2024.
 
 
AMOON GROWTH FUND II L.P.
BY: AMOON GROWTH FUND II G.P., L.P., ITS GENERAL PARTNER
BY:  AMOON GROWTH II GENERAL PARTNER LTD., ITS GENERAL PARTNER
 
By:
/s/ Dr. Yair C. Schindel
 
 
Name:
Title:
Dr. Yair C. Schindel
Director
 
 
AMOON GROWTH FUND II G.P., L.P.,
BY:  AMOON GROWTH II GENERAL PARTNER LTD., ITS GENERAL PARTNER
 
 
By:
/s/ Dr. Yair C. Schindel
 
 
Name:
Title:
Dr. Yair C. Schindel
Director

 
AMOON GROWTH II GENERAL PARTNER LTD.
 
 
By:
/s/ Dr. Yair C. Schindel
 
 
Name:
Title:
Dr. Yair C. Schindel
Director
 
 
AMOON EDGE LIMITED PARTNERSHIP
BY:  AMOON EDGE GP LTD., ITS GENERAL PARTNER
 
 
By:
/s/ Dr. Yair C. Schindel
 
 
Name:
Title:
Dr. Yair C. Schindel
Director
 
Page 18 of 19 Pages

 
AMOON EDGE GP LTD.
 
 
By:
/s/ Dr. Yair C. Schindel
 
 
Name:
Title:
Dr. Yair C. Schindel
Director

 
HILLIYON HOLDINGS LTD.
 
 
By:
/s/ Dr. Yair C. Schindel
 
 
Name:
Title:
Dr. Yair C. Schindel
Director

 
BERKO CAPITAL LTD.
 
 
By:
/s/ Dr. Tomer Berkovitz
 
 
Name:
Title:
Dr. Tomer Berkovitz
Director

 
DR. YAIR C. SCHINDEL
 
/s/ Dr. Yair C. Schindel

 
DR. TOMER BERKOVITZ
 
 
/s/ Dr. Tomer Berkovitz

Page 19 of 19 Pages
Get the next $AKYA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AKYA

DatePrice TargetRatingAnalyst
11/15/2024$7.00 → $5.00Buy → Hold
Craig Hallum
8/6/2024Overweight → Equal-Weight
Morgan Stanley
8/6/2024Buy → Neutral
BTIG Research
8/6/2024Overweight → Neutral
JP Morgan
6/21/2024$7.50Buy
Craig Hallum
12/14/2023Neutral
Guggenheim
7/5/2023$18.00Overweight
JP Morgan
2/2/2023$14.00Buy
UBS
More analyst ratings

$AKYA
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences

    Tikvah Management LLC (together with its affiliates, "Tikvah" or "we"), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. (NASDAQ:QTRX) ("Quanterix" or the "Company"), today announced that it intends to vote AGAINST the Company's proposed merger with Akoya Biosciences, Inc. ("Akoya") (NASDAQ:AKYA) at the upcoming Quanterix Special Meeting of shareholders. As a significant investor in the Company since 2018, Tikvah believes the proposed merger is not in the best interest of Quanterix's shareholders. Tikvah echoes the public comments made by other investors opposing the merger, including that the proposed transaction undervalues Quanterix's shares, there would

    $AKYA
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

  • Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today's Earnings Call

    Believes Proposed Transaction with Akoya Significantly Undervalues Quanterix Encourages Shareholders to Vote Against Transaction to Protect Long-Term Value of their Investment Kent Lake PR LLC ("Kent Lake") is a holder of 7.47% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX). Kent Lake has previously issued a public presentation detailing its opposition to the Company's proposed transaction (the "Transaction") with Akoya Biosciences ("Akoya") (NASDAQ:AKYA), and has also nominated three highly qualified, independent candidates for election to the Company's Board of Directors (the "Board"). Kent Lake urges Quanterix management to addres

    $AKYA
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

  • Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

    MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024. "Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued capital equipment purchases, by successfully strengthening gross margins, reducing operating expenses and advancing our companion diagnostics programs throughout the year. We remain optimistic about the long-term growth outlook of Akoya's leading spatial biology solutions," said Brian McKelligon, CEO of Akoya. "In 2024, Akoya achieved multiple milestones, i

    $AKYA
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$AKYA
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AKYA
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AKYA
 SEC Filings

See more

$AKYA
 Leadership Updates

Live Leadership Updates

See more

  • Akoya Biosciences Announces Leadership Transition

    Joe Driscoll to Retire After More than Four Successful Years as Chief Financial Officer Johnny Ek Appointed as new Chief Financial Officer MARLBOROUGH, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that Chief Financial Officer Joe Driscoll is retiring from his position, effective March 20, 2023. Johnny Ek has been appointed as the company's new Chief Financial Officer, effective immediately. Mr. Driscoll will continue to serve as a consultant of the company as Akoya executes a seamless transition between the two leaders. Mr. Driscoll joined Akoya in April 2019 and has overseen the company's financ

    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

  • Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel

    MARLBOROUGH, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced the appointment of Jennifer Kamocsay as General Counsel. Ms. Kamocsay will oversee all company legal activities and provide strategic guidance and corporate governance oversight. "We are excited to welcome Jennifer to our leadership team," said Brian McKelligon, Chief Executive Officer of Akoya. "Her deep legal expertise and insight will be invaluable as we continue to advance our spatial biology platform and establish additional partnerships to support discovery, translational, and clinical markets." Ms. Kamocsay most recently served as Gen

    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

  • Akoya Biosciences Announces Ehab A. El-Gabry, MD, as Chief Medical Officer

    MARLBOROUGH, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced the appointment of Dr. Ehab A. El-Gabry as the company's Chief Medical Officer (CMO). In this newly created position, Dr. El-Gabry will lead Akoya's strategy in advancing the use of its spatial phenotyping solutions in the clinical setting. Dr. El-Gabry brings a wealth of experiences that are critical to the company's vision of advancing spatial phenotyping in precision medicine and cancer care. He is a board-certified pathologist who served as the Senior Medical Director for Roche Tissue Diagnostics Personalized Health Care Solutions (PHCS). As the

    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$AKYA
 Financials

Live finance-specific insights

See more

  • Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

    MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024. "Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued capital equipment purchases, by successfully strengthening gross margins, reducing operating expenses and advancing our companion diagnostics programs throughout the year. We remain optimistic about the long-term growth outlook of Akoya's leading spatial biology solutions," said Brian McKelligon, CEO of Akoya. "In 2024, Akoya achieved multiple milestones, i

    $AKYA
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

  • Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers

    Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across translational, academic and pharma applications Expects to generate approximately $40 million of annual cost synergies by the end of 2026 with path to positive free cash flow generation in 2026 Combined cash position of approximately $175 million with no expected debt at closing to pursue future growth initiatives Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ

    $AKYA
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

  • Akoya Biosciences Reports Third Quarter 2024 Financial Results

    MARLBOROUGH, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2024. "Our third-quarter results came in below expectations, largely due to ongoing capital equipment purchase constraints seen across the life science tools market. We remain optimistic about the long-term growth outlook of our industry, but we recognize the current environment will pose temporary challenges. We proactively anticipated this with our recent organizational restructuring, which, while difficult and temporarily disruptive this quarter, was the right decision and en

    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$AKYA
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more